Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early Alzheimer’s Disease Carrying Apolipoprotein E4 Genotype
Restricted accessResearch articleFirst published online July 21, 2020
Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early Alzheimer’s Disease Carrying Apolipoprotein E4 Genotype
Neuroinflammatory cytokines can play a pivotal role in Alzheimer’s disease (AD) contributing to the evolution of degenerative processes.
Objective:
We aimed at evaluating the levels of cerebrospinal fluid (CSF) inflammatory cytokines, chemokines, and growth factors in subjects with diagnosis of amnestic mild cognitive impairment and mild AD.
Methods:
We evaluated CSF contents of inflammatory cytokines in 66 patients divided according to the NIA-AA research framework and the APOE genotype. CSF of a group of cognitively unimpaired individuals (n = 23) was evaluated as control. All patients were evaluated for 24 months using Mini-Mental State Examination (MMSE).
Results:
We found significant increased levels of IL-4, IL-6, IL-8, and G-CSF in the CSF of A+/T–APOE4 carriers, respect to A+/T–patients homozygous for APOE3, respect to A+/T+ patients, regardless the APOE status, and respect to controls. Over a period of 24 months, A+/T–APOE4 carriers, with increased levels of cytokines, showed a preserved cognitive evaluation when compared to the other subgroups of patients (delta MMSE at 24 months respect to baseline: 0.10±0.35; p < 0.05).
Conclusion:
Our data suggest that during early phases of AD, in APOE4 carriers, Aβ pathology likely induces a specific cytokines pattern synthesis associated to cognitive preservation. These data highlight the different role that neuroinflammation can play in AD pathology based on the presence of specific CSF biomarkers and on the APOE status.
SelkoeDJ, HardyJ (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med8, 595–608.
2.
SkaperSD, FacciL, ZussoM, GiustiP (2018) An inflammation-centric view of neurological disease: Beyond the neuron. Front Cell Neurosci12, 72.
3.
MosherKI, Wyss-CorayT (2014) Microglial dysfunction in brain aging and Alzheimer’s disease. Biochem Pharmacol88, 594–604.
4.
ZhengC, ZhouXW, WangJZ (2016) The dual roles of cytokines in Alzheimer’s disease: Update on interleukins, TNF-α, TGF-β and IFN-γ. Transl Neurodegener5, 7.
5.
UdeochuJC, SheaJM, VilledaSA (2016) Microglia communication: Parallels between aging and Alzheimer’s disease. Clin Exp Neuroimmunol7, 114–125.
6.
MichelucciA, HeurtauxT, GrandbarbeL, MorgaE, HeuschlingP (2009) Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol210, 3–12.
7.
AlasmariF, AlshammariMA, AlasmariAF, AlanaziWA, AlhazzaniK (2018) Neuroinflammatory cytokines induce amyloid beta neurotoxicity through modulating amyloid precursor protein levels/metabolism. Biomed Res Int2018, 3087475.
8.
HardyJ, SelkoeDJ (2002) The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science297, 353–356.
9.
Lasagna-ReevesCA, Castillo-CarranzaDL, SenguptaU, ClosAL, JacksonGR, KayedR (2011) Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener6, 39.
10.
IqbalK, LiuF, GongCX (2016) Tau and neurodegenerative disease: The story so far. Nat Rev Neurol12, 15–27.
11.
FáM, PuzzoD, PiacentiniR, StaniszewskiA, ZhangH, BaltronsMA, Li PumaDD, ChatterjeeI, LiJ, SaeedF, BermanHL, RipoliC, GulisanoW, GonzalezJ, TianH, CostaJA, LopezP, DavidowitzE, YuWH, HaroutunianV, BrownLM, PalmeriA, SigurdssonEM, DuffKE, TeichAF, HonigLS, SierksM, MoeJG, D’AdamioL, GrassiC, KanaanNM, FraserPE, ArancioO (2016) Extracellular tau oligomers produce an immediate impairment of LTP and memory. Sci Rep6, 19393.
12.
Van der VliesAE, VerweyNA, BouwmanFH, BlankensteinMA, KleinM, ScheltensP, van der FlierWM (2009) CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology72, 1056–1061.
13.
KochG, BelliL, GiudiceTL, Di LorenzoF, SancesarioGM, SorgeR, BernardiniS, MartoranaA (2013) Frailty among Alzheimer’s disease patients. CNS Neurol Disord Drug Targets12, 507–511.
14.
KochG, Di LorenzoF, Del OlmoMF, BonníS, PonzoV, CaltagironeC, BozzaliM, MartoranaA (2016) Reversal of LTP-like cortical plasticity in Alzheimer’s disease patients with tau-related faster clinical progression. J Alzheimers Dis50, 605–616.
15.
KochG, EspositoZ, KusayanagiH, MonteleoneF, CodecáC, Di LorenzoF, CaltagironeC, BernardiG, MartoranaA (2011) CSF tau levels influence cortical plasticity in Alzheimer’s disease patients. . J Alzheimers Dis26, 181–186.
16.
KochG, Di LorenzoF, LoizzoS, MottaC, TravaglioneS, BaiulaM, RimondiniR, PonzoV, BonnìS, TonioloS, SallustioF, BozzaliM, CaltagironeC, CampanaG, MartoranaA (2017) CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer’s disease. Sci Rep7, 13728.
TaipaR, das NevesSP, SousaAL, FernandesJ, PintoC, CorreiaAP, SantosE, PintoPS, CarneiroP, CostaP, SantosD, AlonsoI, PalhaJ, MarquesF, CavacoS, SousaN (2019) Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer’s disease and their correlation with cognitive decline. Neurobiol Aging76, 125–132.
22.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
23.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
24.
Di LorenzoF, MottaC, BonnìS, MercuriNB, CaltagironeC, MartoranaA, KochG (2019) LTP-like cortical plasticity is associated with verbal memory impairment in Alzheimer’s disease patients. Brain Stimul12, 148–151.
25.
MartoranaA, EspositoZ, Di LorenzoF, GiacobbeV, SancesarioGM, BucchiG, BonnìS, BernardiniS, SorgeR, SancesarioG, BernardiG, CaltagironeC, KochG (2012) CSF levels of Aβ1-42 relationship with cholinergic cortical activity in Alzheimer’s disease patients. J Neural Transm119, 771–778.
26.
LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
27.
BunceD, FratiglioniL, SmallBJ, WinbladB, BäckmanL (2004) APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology63, 816–821.
28.
HoltzmanDM, BalesKR, TenkovaT, FaganAM, ParsadanianM, SartoriusLJ, MackeyB, OlneyJ, McKeelD, WozniakD, PaulSM (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A97, 2892–2897.
29.
MahleyRW, WeisgraberKH, HuangY (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci U S A103, 5644–5651.
30.
GruolDL (2015) IL-6 regulation of synaptic function in the CNS. Neuropharmacology96, 42–54.
31.
HettingerJC, LeeH, BuG, HoltzmanDM, CirritoJR (2018) AMPA-ergic regulation of amyloid-β levels in an Alzheimer’s disease mouse model. Mol Neurodegener13, 22.
32.
ZalcmanS, Green-JohnsonJM, MurrayL (1994) Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res643, 40–49.
33.
GadaniSP, CronkJC, NorrisGT, KipnisJ (2012) IL-4 in the brain: A cytokine to remember. J Immunol189, 4213–4219.
34.
ShimizuE, KawaharaK, KajizonoM, SawadaM, NakayamaH (2008) IL-4-induced selective clearance of oligomeric beta-amyloid peptide (1-42) by rat primary type 2 microglia. J Immunol181, 6503–6513.
35.
FranciosiS, RyuJK, ChoiHB, RadovL, KimSU, McLarnonJG (2006) Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1-42-induced cell signaling and functional responses in human microglia. J Neurosci26, 11652–11664.
36.
Ashutosh, KouW, CotterR, BorgmannK, WuL, PersidskyR, SakhujaN, GhorpadeA (2011) CXCL8 protects human neurons from amyloid-β-induced neurotoxicity: Relevance to Alzheimer’s disease. Biochem Biophys Res Commun412, 565–571.
37.
SopovaK, GatsiouK, StellosK, LaskeC (2014) Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer’s disease: From pathophysiology to novel treatment strategies. . Curr Alzheimer Res11, 27–39.
38.
MarslandAL, GianarosPJ, KuanDC, SheuLK, KrajinaK, ManuckSB (2015) Brain morphology links systemic inflammation to cognitive function in midlife adults.195-204 (2015). Brain Behav Immun48.
39.
AboudO, MrakRE, BoopF, GriffinST (2012) Apolipoprotein epsilon 3 alleles are associated with indicators of neuronal resilience. BMC Med10, 35.
40.
LeeYM, HaJK, ParkJM, LeeBD, MoonE, ChungYI, KimJH, KimHJ, MunCW, KimTH, KimYH (2016) Impact of Apolipoprotein E4 polymorphism on the gray matter volume and the white matter integrity in subjective memory impairment without white matter hyperintensities: Voxel-based morphometry and tract-based spatial statistics study under 3-Tesla MRI. J Neuroimaging26, 144–149.
41.
StrittmatterWJ, SaundersAM, SchmechelD, Pericak-VanceM, EnghildJ, SalvesenGS, RosesAD (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A90, 1977–1981.
SochockaM, DinizBS, LeszekJ (2017) Inflammatory response in the CNS: Friend or foe?Mol Neurobiol54, 8071–8089.
44.
BlennowK, HampelH, WeinerM, ZetterbergH (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol6, 131–144.
45.
ParachikovaA, VasilevkoV, CribbsDH, LaFerlaFM, GreenKN (2010) Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis21, 527–542.
46.
ShiJQ, ShenW, ChenJ, WangBR, ZhongLL, ZhuYW, ZhuHQ, ZhangQQ, ZhangYD, XuJ (2011) Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res1368, 239–247.
